Principal Financial Group Inc. Buys New Shares in Iradimed Corporation (NASDAQ:IRMD)

Principal Financial Group Inc. purchased a new stake in shares of Iradimed Corporation (NASDAQ:IRMD) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,894 shares of the medical equipment provider’s stock, valued at approximately $246,000.

Several other large investors have also recently added to or reduced their stakes in IRMD. Charles Schwab Investment Management Inc. increased its position in shares of Iradimed by 189.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 66,632 shares of the medical equipment provider’s stock valued at $3,351,000 after purchasing an additional 43,635 shares during the period. Oak Ridge Investments LLC bought a new stake in Iradimed in the 3rd quarter valued at $2,188,000. Eagle Asset Management Inc. acquired a new position in shares of Iradimed in the 3rd quarter valued at $1,239,000. Albert D Mason Inc. bought a new position in shares of Iradimed during the 3rd quarter worth about $737,000. Finally, Barclays PLC boosted its position in shares of Iradimed by 113.9% during the 3rd quarter. Barclays PLC now owns 23,774 shares of the medical equipment provider’s stock valued at $1,196,000 after acquiring an additional 12,657 shares in the last quarter. Institutional investors and hedge funds own 92.34% of the company’s stock.

Iradimed Stock Up 1.7 %

NASDAQ:IRMD opened at $56.49 on Tuesday. The firm has a market capitalization of $715.90 million, a PE ratio of 38.69 and a beta of 0.81. Iradimed Corporation has a 12-month low of $40.18 and a 12-month high of $57.95. The firm has a 50-day moving average price of $53.83 and a 200 day moving average price of $49.30.

Iradimed Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, November 25th. Stockholders of record on Friday, November 15th were issued a $0.15 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 1.06%. Iradimed’s payout ratio is presently 41.10%.

Insider Buying and Selling

In other Iradimed news, CFO John Glenn sold 2,500 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $54.18, for a total value of $135,450.00. Following the transaction, the chief financial officer now directly owns 4,383 shares in the company, valued at $237,470.94. The trade was a 36.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 37.10% of the stock is owned by corporate insiders.

Iradimed Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.